Total Payments
$39,413
2024 Payments
$2,389
Companies
9
Transactions
56
Medicare Patients
2,260
Medicare Billing
$502,774
Payment Breakdown by Category
Other$21,192 (53.8%)
Consulting$11,480 (29.1%)
Travel$4,236 (10.7%)
Food & Beverage$2,501 (6.3%)
Education$3.78 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,200 | 11 | 48.7% |
| Consulting Fee | $11,480 | 8 | 29.1% |
| Travel and Lodging | $4,236 | 10 | 10.7% |
| Food and Beverage | $2,501 | 25 | 6.3% |
| Honoraria | $1,992 | 1 | 5.1% |
| Education | $3.78 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $23,315 | 24 | $0 (2022) |
| PAVmed Inc. | $5,000 | 3 | $0 (2022) |
| PFIZER INC. | $2,389 | 6 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $2,385 | 2 | $0 (2023) |
| Seagen Inc. | $2,248 | 4 | $0 (2023) |
| Dendreon Pharmaceuticals LLC | $2,096 | 4 | $0 (2020) |
| Exelixis Inc. | $1,634 | 10 | $0 (2018) |
| Genentech USA, Inc. | $213.76 | 2 | $0 (2019) |
| Foundation Medicine, Inc. | $132.89 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,389 | 6 | PFIZER INC. ($2,389) |
| 2023 | $1,106 | 3 | Janssen Scientific Affairs, LLC ($825.00) |
| 2022 | $2,132 | 4 | PAVmed Inc. ($1,500) |
| 2021 | $3,500 | 1 | PAVmed Inc. ($3,500) |
| 2020 | $8,900 | 9 | Janssen Biotech, Inc. ($3,750) |
| 2019 | $19,620 | 22 | Janssen Biotech, Inc. ($19,060) |
| 2018 | $1,634 | 10 | Exelixis Inc. ($1,634) |
| 2017 | $132.89 | 1 | Foundation Medicine, Inc. ($132.89) |
All Payment Transactions
56 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/08/2024 | PFIZER INC. | TALZENNA (Drug), XTANDI | Education | In-kind items and services | $3.78 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | PFIZER INC. | PADCEV (Biological) | Honoraria | Cash or cash equivalent | $1,992.00 | General |
| Category: Oncology | ||||||
| 05/31/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 05/31/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $71.24 | General |
| Category: Oncology | ||||||
| 05/31/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $39.11 | General |
| Category: Oncology | ||||||
| 01/27/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $147.59 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2023 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $151.74 | General |
| 02/17/2023 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $129.39 | General |
| 01/11/2023 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/19/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $505.00 | General |
| Category: Oncology | ||||||
| 05/30/2022 | PAVmed Inc. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 03/30/2022 | PAVmed Inc. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 02/17/2022 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $126.55 | General |
| 12/02/2021 | PAVmed Inc. | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 11/18/2020 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| Category: Oncology | ||||||
| 11/07/2020 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/25/2020 | Seagen Inc. | PADCEV (Biological) | Consulting Fee | Cash or cash equivalent | $1,840.00 | General |
| Category: Oncology | ||||||
| 07/27/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: Oncology | ||||||
| 06/30/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: Oncology | ||||||
| 05/26/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Oncology | ||||||
| 05/04/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 02/13/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 02/13/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 12/19/2019 | Janssen Biotech, Inc. | Erleada (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: Oncology | ||||||
| 12/09/2019 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $124.26 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 563 | 1,189 | $735,941 | $138,734 |
| 2022 | 6 | 558 | 1,108 | $751,751 | $128,335 |
| 2021 | 7 | 547 | 1,113 | $713,440 | $129,212 |
| 2020 | 7 | 592 | 1,130 | $528,522 | $106,494 |
Total Patients
2,260
Total Services
4,540
Medicare Billing
$502,774
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 185 | 472 | $335,800 | $58,798 | 17.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 80 | 226 | $136,659 | $27,465 | 20.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 151 | $56,270 | $16,565 | 29.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 72 | 72 | $51,610 | $10,989 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 74 | 121 | $78,896 | $9,884 | 12.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 71 | $35,442 | $5,302 | 15.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 33 | $24,981 | $5,278 | 21.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 17 | 18 | $7,884 | $1,928 | 24.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $5,067 | $1,503 | 29.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 11 | 14 | $3,332 | $1,023 | 30.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 180 | 431 | $342,024 | $55,013 | 16.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 80 | 169 | $113,094 | $20,791 | 18.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 152 | $55,936 | $14,312 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 91 | 161 | $108,648 | $13,001 | 12.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 64 | 64 | $53,006 | $10,386 | 19.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 27 | 27 | $18,756 | $4,937 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 42 | 64 | $37,788 | $4,935 | 13.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 19 | 19 | $13,826 | $2,892 | 20.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 21 | 21 | $8,673 | $2,068 | 23.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 126 | 345 | $260,070 | $45,174 | 17.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 100 | 211 | $141,832 | $18,663 | 13.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 64 | 143 | $83,058 | $18,100 | 21.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 40 | 134 | $49,312 | $12,792 | 25.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 66 | 66 | $61,014 | $11,161 | 18.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 55 | 109 | $63,808 | $8,662 | 13.6% |
About Dr. Sumit Shah, MD
Dr. Sumit Shah, MD is a Hematology & Oncology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2010. The National Provider Identifier (NPI) number assigned to this provider is 1942529227.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sumit Shah, MD has received a total of $39,413 in payments from pharmaceutical and medical device companies, with $2,389 received in 2024. These payments were reported across 56 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($19,200).
As a Medicare-enrolled provider, Shah has provided services to 2,260 Medicare beneficiaries, totaling 4,540 services with total Medicare billing of $502,774. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Stanford, CA
- Active Since 05/25/2010
- Last Updated 04/16/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1942529227
Products in Payments
- Erleada (Drug) $19,060
- ERLEADA (Drug) $6,640
- PADCEV (Biological) $3,942
- PROVENGE (Drug) $2,096
- INLYTA (Drug) $147.59
- FOUNDATIONONE (Device) $132.89
- TECENTRIQ (Biological) $113.76
- TALZENNA (Drug) $3.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Stanford
Everett Meyer, Md Phd, MD PHD
Hematology & Oncology — Payments: $2.1M
Hematology & Oncology $2.1M
Sandra Horning, M.d, M.D
Hematology & Oncology — Payments: $1.9M
Hematology & Oncology $1.9M
George Fisher, Md, MD
Hematology & Oncology — Payments: $202,617
Hematology & Oncology $202,617
Joel Neal, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $169,917
Hematology & Oncology $169,917
Lipika Goyal, Md, MD
Hematology & Oncology — Payments: $157,376
Hematology & Oncology $157,376
David Miklos, M.d., Ph. D, M.D., PH. D
Hematology & Oncology — Payments: $131,666
Hematology & Oncology $131,666